SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (“Salona Global”, “SGMD” or the “Company”) (TSXV:SGMD) today announced highlights for the third fiscal quarter of 2023, ending November 30, 2022. The Company posted 211% year-over-year revenue growth, 231% year-over-year gross margin growth, and improved gross margin as a percentage of revenue by 10% over last quarter to 33%. The Company also provided an update on the progress toward closing the recently announced acquisition and its focus to list on a US stock exchange.
Salona Global in its current form listed in June 2021 on the TSX Venture Exchange (the “Exchange”) with a plan to become a leading medical device company servicing physical therapy clinics, athletic training rooms and orthopedic doctors. Since listing, the management has built a team of industry professionals that has generated $48.4 million in cumulative revenue over the past 6 quarters and has completed 5 transactions. As part of the Company’s plan to achieve gross margins of 40% as a percentage of revenue, the Company is focused on higher margin revenue opportunities and has increased gross margin as a percentage of revenue by 10% over the last quarter.
The Company is currently working to close the large and complex Biodex Medical Systems, Inc. acquisition, previously announced November 29, 2022, that would add significant revenue, customers and product lines to the existing business. The conditions to close include domestic and global third party and regulatory approvals, making the precise timing to close difficult to predict.
Finally, the Company has formally engaged investment banking firm Maxim Group based in New York City to expose the Company to potential US investors in an effort to position itself for a potential US listing. The Company intends that it would maintain its Canadian listing even after any potential US listing is effective.
Financial and Business Headlines
Revenues
Profits
Expansion of Bank Line
On January 13, 2023, the Company increased its aggregate credit line availability by up to $5.5 million pursuant to a Loan and Security Agreement with Pathward, National Association, which is in addition to an existing credit facility with Pathward through the Company’s South Dakota Partners subsidiary. This new Loan and Security Agreement has a variable interest rate of 0.75% in excess of the rate shown in the Wall Street Journal as the prime rate, is payable on demand and is secured by all of the assets of three operating subsidiaries of the Company (Simbex, Mio-Guard and Damar) as borrowers and guaranteed by the Company.
Our Focus
“Our focus for the last two quarters has been to build a solid foundation for future acquisitions, including the Biodex deal,” said CEO Luke Faulstick. “Besides strengthening our team to make the large and complex Biodex acquisition successful post close, we have also increased our focus on higher margin medical device product lines associated with our developing IP. In the long run, this will give us the ability to quickly deliver on our high margin medical device revenue growth plan in the coming quarters.”
“This quarter, just our sixth full quarter since our re-listing, also gives us the opportunity to highlight our year-over-year revenue and profit growth rate,” said Executive Chairman Les Cross. “This growth comes from our investments in five strong engines of growth: (1) M&A; (2) product development; (3) product IP acquisitions; (4) product distribution agreements; and (5) organic growth post-acquisition.”
Earnings Call
On Tuesday, January 17, 2023, at 5:00 p.m. (Eastern Time), Executive Chairman Les Cross, CEO Luke Faulstick, and CFO Dennis Nelson will hold an earnings call (see details below) to discuss the third quarter financial results.
Fiscal Third Quarter Earnings Call
Toll Free Dial In: +1 (800) 245-3047
Direct Dial: +1 (203) 518-9765
Conference ID: SALONA
Sign up at http://tinyurl.com/salonaglobalnewsletter for updates on Salona Global delivered directly to your inbox.
Full Financial Statements
Condensed financial statements for the third quarter ending November 30, 2022 are attached at end of this release. The full financial statements and related management discussion and analysis (in the form of a quarterly report on Form 10-Q) will be filed with the United States Securities and Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com, after the market closes today.
For more information please contact:
Luke Faulstick
Chief Executive Officer
Tel: 1 (800) 760-6826
Email: Info@Salonaglobal.com
Non-GAAP Measures
This press release refers to “order book backlog” and “Adjusted EBITDA” which are non-GAAP and non-IFRS financial measures that do not have standardized meanings prescribed by GAAP or IFRS. The Company’s presentation of these financial measures may not be comparable to similarly titled measures used by other companies. These non-GAAP financial measures assist the Company’s management in comparing its operating performance over time because certain items may obscure underlying business trends and make comparisons of long-term performance difficult, as they are of a nature and/or size that occur with inconsistent frequency or relate to discrete acquisition plans that are fundamentally different from the ongoing operating plans of the Company. The Company’s management also believes that presenting these measures allows investors to view the Company’s performance using the same measures that the Company uses in evaluating its financial and business performance and trends.
Order book backlog as used in this press release is calculated as committed customer orders to deliver products and services at a future date.
Adjusted EBITDA is defined as net loss excluding: stock based compensation, amortization, depreciation, interest expense, foreign exchange gain, change in fair value of earn-out consideration, change in fair value of contingent consideration, transaction costs, and income tax expense.
| 3 months ended | 9 months ended | |||||||||||||||
| November 30, | November 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Adjusted EBITDA | $ | (159,716 | ) | $ | 302,536 | $ | 1,267,688 | $ | 577,357 | |||||||
| Stock Based Compensation | (380,938 | ) | (292,492 | ) | (1,248,710 | ) | (757,792 | ) | ||||||||
| Net (loss) income before the undernoted | (540,654 | ) | 10,044 | 18,978 | (180,435 | ) | ||||||||||
| Amortization of intangible asset | (301,990 | ) | (165,552 | ) | (786,842 | ) | (244,340 | ) | ||||||||
| Depreciation of property and equipment | (147,622 | ) | (65,458 | ) | (292,476 | ) | (131,414 | ) | ||||||||
| Amortization of right-of-use asset | (285,967 | ) | (67,817 | ) | (508,185 | ) | (106,700 | ) | ||||||||
| Interest Expense | (226,573 | ) | (121,518 | ) | (508,649 | ) | (265,602 | ) | ||||||||
| Foreign exchange (loss) gain | (13,703 | ) | (48,934 | ) | (13,471 | ) | (38,397 | ) | ||||||||
| Change in fair value of earn-out consideration | - | - | (2,451,600 | ) | - | |||||||||||
| Change in fair value of contingent consideration | 980,730 | - | (7,532,300 | ) | - | |||||||||||
| Gain on share for debt settlement | - | - | - | 15,538 | ||||||||||||
| Transaction costs including legal, financial, audit and US & Canadian regulatory expenses | (1,054,602 | ) | (1,044,455 | ) | (2,403,285 | ) | (2,269,923 | ) | ||||||||
| Current income tax expense | (11,754 | ) | (7 | ) | (41,786 | ) | (1,995 | ) | ||||||||
| Deferred income tax recovery | 73,538 | - | 192,721 | - | ||||||||||||
| Net Loss | $ | (1,528,597 | ) | $ | (1,503,697 | ) | $ | 14,326,895 | ) | $ | (3,223,268 | ) | ||||
Additional Information
There can be no assurance that any acquisition (including the acquisition contemplated herein and the targets Salona Global is currently negotiating within its pipeline) will be completed or the timing of any acquisitions. Completion of any transaction will be subject to, amongst other things, negotiation and execution of definitive agreements, applicable director, shareholder and regulatory approvals.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
Unless otherwise specified, all dollar amounts in this press release are expressed in Canadian dollars.
Certain statements contained in this press release constitute “forward-looking information” within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws. These statements can be identified by the use of forward-looking terminology such as “expects” “believes”, “estimates”, “may”, “would”, “could”, “should”, “potential”, “will”, “seek”, “intend”, “plan”, and “anticipate”, and similar expressions as they relate to the Company, including: the Company financing and closing the acquisition disclosed herein; the Company’s plan to achieve gross margins of 40%; the results of engaging an investment banking firm in New York City; the completion of a proposed listing on NASDAQ; and the Company’s intention to remain listed in Canada even after any potential US listing is effective. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company’s current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties, and assumptions. Salona cautions that the forward-looking statements contained herein are qualified by important factors that could cause actual results to differ materially from those reflected by such statements. Such factors include but are not limited to the general business and economic conditions in the regions in which Salona operates; the ability of Salona to execute on key priorities, including the successful completion of acquisitions, business retention, and strategic plans and to attract, develop and retain key executives; difficulty integrating newly acquired businesses; ongoing or new disruptions in the supply chain, the extent and scope of such supply chain disruptions, and the timing or extent of the resolution or improvement of such disruptions; the ability to implement business strategies and pursue business opportunities; disruptions in or attacks (including cyber-attacks) on Salona’s information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which Salona is exposed; the failure of third parties to comply with their obligations to Salona or its affiliates; the impact of new and changes to, or application of, current laws and regulations; granting of permits and licenses in a highly regulated business; the overall difficult litigation environment, including in the United States; increased competition; changes in foreign currency rates; increased funding costs and market volatility due to market illiquidity and competition for funding; the availability of funds and resources to pursue operations; critical accounting estimates and changes to accounting standards, policies, and methods used by Salona; the occurrence of natural and unnatural catastrophic events and claims resulting from such events; and risks related to COVID-19 including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity, financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; as well as those risk factors discussed or referred to in Salona’s disclosure documents filed with United States Securities and Exchange Commission and available at www.sec.gov, and with the securities regulatory authorities in certain provinces of Canada and available at www.sedar.com. Should any factor affect Salona in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Salona does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
| SALONA GLOBAL MEDICAL DEVICE CORPORATION | ||||||||||||||||
| Unaudited Interim Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| 3 months ended | 9 months ended | |||||||||||||||
| November 30, | November 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenues | $ | 10,547,652 | $ | 5,286,702 | $ | 30,640,439 | $ | 9,850,915 | ||||||||
| Cost of revenue: | ||||||||||||||||
| Direct service personnel | 1,472,850 | 953,260 | 4,465,024 | 1,230,443 | ||||||||||||
| Direct material costs | 5,269,741 | 2,431,065 | 15,146,076 | 5,306,949 | ||||||||||||
| Other direct costs | 309,901 | 239,741 | 863,401 | 239,741 | ||||||||||||
| Total cost of revenue | 7,052,492 | 3,624,066 | 20,474,501 | 6,777,133 | ||||||||||||
| Gross margin | 3,495,160 | 1,662,636 | 10,165,938 | 3,073,782 | ||||||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | 4,035,814 | 1,652,592 | 10,146,960 | 3,254,217 | ||||||||||||
| Total operating expenses | 4,035,814 | 1,652,592 | 10,146,960 | 3,254,217 | ||||||||||||
| Net (loss) income before the undernoted | (540,654 | ) | 10,044 | 18,978 | (180,435 | ) | ||||||||||
| Amortization of intangible assets | (301,990 | ) | (165,552 | ) | (786,842 | ) | (244,340 | ) | ||||||||
| Depreciation of property and equipment | (147,622 | ) | (65,458 | ) | (292,476 | ) | (131,414 | ) | ||||||||
| Amortization of right-of-use assets | (285,967 | ) | (67,817 | ) | (508,185 | ) | (106,700 | ) | ||||||||
| Interest expense | (226,573 | ) | (121,518 | ) | (508,649 | ) | (265,602 | ) | ||||||||
| Foreign exchange (loss) | (13,703 | ) | (48,934 | ) | (13,471 | ) | (38,397 | ) | ||||||||
| Gain on debt settlement | - | - | - | 15,538 | ||||||||||||
| Change in fair value of earn-out consideration | - | - | (2,451,600 | ) | - | |||||||||||
| Change in fair value of contingent consideration | 980,730 | - | (7,532,300 | ) | - | |||||||||||
| Transaction costs including legal, financial, audit, US & Canadian regulatory expenses | (1,054,602 | ) | (1,044,455 | ) | (2,403,285 | ) | (2,269,923 | ) | ||||||||
| Net loss before taxes | (1,590,381 | ) | (1,503,690 | ) | (14,477,830 | ) | (3,221,273 | ) | ||||||||
| Current income tax expense | (11,754 | ) | (7 | ) | (41,786 | ) | (1,995 | ) | ||||||||
| Deferred income tax recovery | 73,538 | - | 192,721 | - | ||||||||||||
| Net loss | $ | (1,528,597 | ) | $ | (1,503,697 | ) | $ | (14,326,895 | ) | $ | (3,223,268 | ) | ||||
| Other comprehensive loss | ||||||||||||||||
| Foreign currency translation gain (loss) | (79,919 | ) | 112,505 | (37,967 | ) | 128,506 | ||||||||||
| Comprehensive loss | $ | (1,608,516 | ) | $ | (1,391,192 | ) | $ | (14,364,862 | ) | $ | (3,094,762 | ) | ||||
| Net loss per share | ||||||||||||||||
| Basic and diluted | $ | (0.03 | ) | $ | (0.03 | ) | $ | (0.26 | ) | $ | (0.08 | ) | ||||
| Weighted average number of common shares outstanding | 55,145,538 | 44,790,162 | 54,585,045 | 41,480,296 | ||||||||||||
| SALONA GLOBAL MEDICAL DEVICE CORPORATION | ||||||||
| Unaudited Interim Condensed Consolidated Balance Sheets | ||||||||
| November 30, | February 28, | |||||||
| 2022 | 2022 | |||||||
| Assets | ||||||||
| Cash and cash equivalents | $ | 3,138,860 | $ | 8,057,100 | ||||
| Accounts receivable, net | 7,797,115 | 6,595,668 | ||||||
| Inventories, net | 8,590,314 | 4,969,439 | ||||||
| Prepaid expenses and other receivables | 478,808 | 412,794 | ||||||
| Total current assets | 20,005,097 | 20,035,001 | ||||||
| Security deposit | 564,694 | 484,975 | ||||||
| Receivables, net of current portion | 191,814 | - | ||||||
| Property and equipment, net | 3,069,273 | 1,460,175 | ||||||
| Right-of-use assets, net | 7,878,162 | 3,941,840 | ||||||
| Intangible assets, net | 9,407,662 | 6,926,582 | ||||||
| Goodwill | 12,544,397 | 9,833,039 | ||||||
| Total assets | $ | 53,661,099 | $ | 42,681,612 | ||||
| Liabilities and stockholders’ equity | ||||||||
| Liabilities | ||||||||
| Line of credit | $ | 6,162,803 | $ | 5,497,249 | ||||
| Accounts payable and accrued liabilities | 6,138,923 | 3,679,396 | ||||||
| Current portion of debt | 193,999 | 174,361 | ||||||
| Current portion of lease liability | 814,797 | 245,257 | ||||||
| Other liabilities | 2,066,165 | 562,262 | ||||||
| Obligation for payment of earn-out consideration | 13,094,513 | 12,997,846 | ||||||
| Total current liabilities | 28,471,200 | 23,156,371 | ||||||
| Debt, net of current portion | 587,229 | 681,758 | ||||||
| Lease liability, net of current portion | 6,026,697 | 3,934,431 | ||||||
| Deferred tax liability | 2,425,195 | 1,755,889 | ||||||
| Total liabilities | 37,510,321 | 29,528,449 | ||||||
| Stockholders’ equity | ||||||||
| Common stock; no par value, unlimited shares authorized; 53,707,780 shares issued and outstanding as of November 30, 2022 (February 28, 2022: 52,539,162) | 38,767,442 | 38,046,097 | ||||||
| Class A shares; no par value, unlimited shares authorized; 3,403,925 shares issued and outstanding as of November 30, 2022 (February 28, 2022: 1,355,425) | 1,800,064 | 480,479 | ||||||
| Class A Shares to be issued: 19,019,000Class A shares to be issued as of November 30, 2022 (February 28, 2022: nil) | 14,264,250 | - | ||||||
| Additional paid-in-capital | 8,042,404 | 6,985,107 | ||||||
| Accumulated other comprehensive income | 968,394 | 1,006,361 | ||||||
| Deficit | (47,691,776 | ) | (33,364,881 | ) | ||||
| Total stockholders’ equity | 16,150,778 | 13,153,163 | ||||||
| Total liabilities and stockholders’ equity | $ | 53,661,099 | $ | 42,681,612 | ||||
| Last Trade: | C$0.005 |
| Daily Volume: | 2,000 |
| Market Cap: | C$299K |
March 17, 2025 November 25, 2024 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
